Medtronic announces FDA clearance for LigaSure™ RAS Maryland instrument on the Hugo™ RAS system
Article excerpt
Highlighted: the sentence this signal was extracted from
Trusted vessel-sealing technology used in more than 45 million procedures worldwide is now cleared for robotic-assisted surgery in the U.S. GALWAY, Ireland, Sept. 16, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT ), a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) has cleared the LigaSure™ RAS Maryland jaw device for use with the Hugo™ robotic-assisted surgery (RAS) system. The clearance expands the instruments available on the Hugo RAS system and brings Medtronic's trusted vessel-sealing technology to U.S. surgeons performing robotic-assisted procedures. As robotic-assisted surgery adoption grows in the U.S., surgeons increasingly expect the same trusted energy instruments in a robotic workflow that they rely on in open and laparoscopic settings. The LigaSure RAS Maryland instrument meets that expectation, pairing a versatile robotic platform with vessel-sealing technology surgeons already know. "Vessel sealing sits at the center of how surgeons work through the most demanding moments of a procedure, and surgeons have trusted LigaSure to do it across open and laparoscopic surgery for decades," said Dr. Matthew Kroh, chief medical officer within the Surgical business at Medtronic and a practicing surgeon. "Bringing that same performance to the Hugo RAS system in the U.S. means surgeons carry the confidence and control they...
Keep reading with a free account
The rest of this article, and every signal for Medtronic, is in your free account.
